Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Olema Pharmaceuticals Inc

OLMA
Current price
10.1 USD -1.33 USD (-11.64%)
Last closed 11.48 USD
ISIN US68062P1066
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 710 103 360 USD
Yield for 12 month -39.95 %
1Y
3Y
5Y
10Y
15Y
OLMA
21.11.2021 - 28.11.2021

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. Address: 780 Brannan Street, San Francisco, CA, United States, 94103

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

27.67 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-377 000 USD

Last Year

-1 658 000 USD

Current Quarter

-94 000 USD

Last Quarter

-88 000 USD

Key Figures OLMA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -122 267 000 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -35.47 %
PEG Ratio
Return On Equity TTM -56.4 %
Wall Street Target Price 27.67 USD
Revenue TTM
Book Value 3.97 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -2.04 USD
Diluted Eps TTM -2.04 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics OLMA

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History OLMA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation OLMA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -3.326
Price Book MRQ 3.126

Financials OLMA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators OLMA

For 52 weeks

8.51 USD 17.23 USD
50 Day MA 12.06 USD
Shares Short Prior Month 8 511 108
200 Day MA 12.16 USD
Short Ratio 16.23
Shares Short 8 495 375
Short Percent 25.76 %